NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Principia Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $48.76 -3.68 (-7.02 %) (As of 04/5/2020 04:00 PM ET) Add Compare Share Today's Range$47.22Now: $48.76▼$52.8850-Day Range$43.50MA: $58.19▼$70.5552-Week Range$25.35Now: $48.76▼$75.65Volume286,371 shsAverage Volume309,697 shsMarket Capitalization$1.61 billionP/E RatioN/ADividend YieldN/ABeta0.87 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPrincipia Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $76.00, Principia Biopharma has a potential upside of 55.9% from its current price of $48.76.Amount of Analyst CoveragePrincipia Biopharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesPrincipia Biopharma has received 79 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPrincipia Biopharma has received 88 “underperform” votes. (Add your “underperform” vote.)Community SentimentPrincipia Biopharma has received 52.69% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Principia Biopharma and other stocks. Vote “Outperform” if you believe PRNB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRNB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPrincipia Biopharma does not currently pay a dividend.Dividend GrowthPrincipia Biopharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Principia Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,377,450.00 in company stock.Percentage Held by InsidersOnly 28.98% of the stock of Principia Biopharma is held by insiders.Percentage Held by Institutions88.25% of the stock of Principia Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Principia Biopharma are expected to grow by 26.46% in the coming year, from ($2.91) to ($3.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Principia Biopharma is -24.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Principia Biopharma is -24.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrincipia Biopharma has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRNB Previous Symbol CUSIPN/A CIKN/A Webhttp://www.principiabio.com/ Phone650-416-7700Debt Debt-to-Equity RatioN/A Current Ratio19.81 Quick Ratio19.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.16 million Price / Sales45.78 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book4.45Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-53,790,000.00 Net MarginsN/A Return on Equity-25.58% Return on Assets-23.19%Miscellaneous Employees65 Outstanding Shares33,010,000Market Cap$1.61 billion Next Earnings Date5/5/2020 (Estimated) OptionableNot Optionable Receive PRNB News and Ratings via Email Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PRNB Rates by TradingView Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions How has Principia Biopharma's stock been impacted by COVID-19 (Coronavirus)? Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRNB stock has decreased by 9.5% and is now trading at $48.76. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Principia Biopharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Principia Biopharma. When is Principia Biopharma's next earnings date? Principia Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Principia Biopharma. How were Principia Biopharma's earnings last quarter? Principia Biopharma Inc (NASDAQ:PRNB) issued its quarterly earnings data on Tuesday, March, 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.02. View Principia Biopharma's earnings history. What price target have analysts set for PRNB? 3 brokerages have issued 12-month price objectives for Principia Biopharma's stock. Their forecasts range from $70.00 to $82.00. On average, they anticipate Principia Biopharma's share price to reach $76.00 in the next year. This suggests a possible upside of 55.9% from the stock's current price. View analysts' price targets for Principia Biopharma. What are Wall Street analysts saying about Principia Biopharma stock? Here are some recent quotes from research analysts about Principia Biopharma stock: 1. According to Zacks Investment Research, "Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs for the treatment of cancers. The company's product pipeline consists of PRN1008, PRN1371 and PRN2246 which are in clinical stage. Principia Biopharma Inc. is based in San Francisco, United States. " (3/17/2020) 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $45 target price after PRNB reported its 2Q19 financial and business update. We remain bullish ahead of what we view as a catalyst-rich 4Q19, with readouts expected for PRN1008 in both pemphigus vulgaris (PV) and immune thrombocytopenia purpura (ITP). We continue to think PRNB’s nuanced medicinal chemistry platform is under appreciated by the Street and, in our view, PRNB has developed a BTK inhibitor, PRN1008, with an improved safety profile allowing for use in autoimmune conditions which is something that has hindered previous BTKi’s. We believe PRN1008’s data generated to date, already suggest an improved safety profile and we think further proof-of-concept data in its two beachhead indications (PV and ITP) in 4Q19 should drive shares meaingfully higher." (8/11/2019) 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $55 price target. Our current valuation is based on the PRN1008 opportunity in PV (86%) followed by incremental contribution from ITP (7%), PRN2246 for MS (5%), and PRN1371 for bladder cancer (2%). In PV, we project a 2022 and 2023 launch in the U.S. and E.U., based on a 50% projected chance of success and $1.0 billion and $570 million in peak sales, respectively. For ITP, we only model the U.S." (7/30/2019) Has Principia Biopharma been receiving favorable news coverage? Press coverage about PRNB stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Principia Biopharma earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutPrincipia Biopharma. Are investors shorting Principia Biopharma? Principia Biopharma saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,774,800 shares, an increase of 15.2% from the February 27th total of 1,540,000 shares. Based on an average daily trading volume, of 266,100 shares, the days-to-cover ratio is currently 6.7 days. Approximately 13.9% of the shares of the stock are short sold. View Principia Biopharma's Current Options Chain. Who are some of Principia Biopharma's key competitors? Some companies that are related to Principia Biopharma include Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Forty Seven (FTSV), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Evotec (EVTCY), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC) and Global Blood Therapeutics (GBT). What other stocks do shareholders of Principia Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Agile Therapeutics (AGRX), Amarin (AMRN), Momo (MOMO), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM) and Krystal Biotech (KRYS). Who are Principia Biopharma's key executives? Principia Biopharma's management team includes the following people: Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)Mr. Martin Babler, CEO & Director (Age 54)Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)Dr. David M. Goldstein, Chief Scientific Officer (Age 53) When did Principia Biopharma IPO? (PRNB) raised $75 million in an initial public offering (IPO) on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. What is Principia Biopharma's stock symbol? Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB." How do I buy shares of Principia Biopharma? Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Principia Biopharma's stock price today? One share of PRNB stock can currently be purchased for approximately $48.76. How big of a company is Principia Biopharma? Principia Biopharma has a market capitalization of $1.61 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe. View additional information about Principia Biopharma. What is Principia Biopharma's official website? The official website for Principia Biopharma is http://www.principiabio.com/. How can I contact Principia Biopharma? Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Do equity income investments outperform growth and income investments?
